Matthew J. Hogan

Former Chief Financial Officer, Secretary, CAO & Head-Investor Relations at DURECT Corp.

Matthew J. Hogan

Matthew J. Hogan

Former Chief Financial Officer, Secretary, CAO & Head-Investor Relations at DURECT Corp.

Overview
Career Highlights

DURECT Corp.
Vermillion, Inc.
Avocet Medical, Inc.

RelSci Relationships

873

Number of Boards

1

Birthday

1960

Age

58

Contact Data
Trying to get in touch with Matthew J. Hogan? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Matthew J. Hogan likely has professional access to. A relationship does not necessarily indicate a personal connection.

Vice President-Chemistry at Rempex Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at DURECT Corp.

Relationship likelihood: Strong

Co-Founder at DURECT Corp.

Relationship likelihood: Strong

Chief Financial Officer at DURECT Corp.

Relationship likelihood: Strong

Vice President-Finance & Corporate Controller at DURECT Corp.

Relationship likelihood: Strong

Chief Patent Counsel at DURECT Corp.

Relationship likelihood: Strong

Chief Executive Officer & Chief Scientific Officer at Adesis, Inc.

Relationship likelihood: Strong

Vice President, R&D Business Development & Principal Scientist at DURECT Corp.

Relationship likelihood: Strong

Senior Vice President, Operations & Corporate Quality Assurance at DURECT Corp.

Relationship likelihood: Strong

Member, Executive Leadership Team at UJA-Federation of New York

Relationship likelihood: Average

Paths to Matthew J. Hogan
Potential Connections via
Relationship Science
You
Matthew J. Hogan
Former Chief Financial Officer, Secretary, CAO & Head-Investor Relations at DURECT Corp.
Education
MBA

The Tuck School of Business at Dartmouth is the graduate business school of Dartmouth College in Hanover, New Hampshire, in the United States. Tuck is one of six Ivy league business schools. Founded in 1900, Tuck was the first institution to offer a master's degree in the field of business administration

B.A. in Economics

Founded in 1769, Dartmouth is a member of the Ivy League and consistently ranks among the world's greatest academic institutions. Dartmouth has forged a singular identity for combining its deep commitment to outstanding undergraduate liberal arts and graduate education with distinguished research and scholarship in the Arts & Sciences and its three leading professional schools—the Geisel School of Medicine, Thayer School of Engineering, and the Tuck School of Business.

Career History
Chief Financial Officer, Secretary, CAO & Head-Investor Relations
2006 - 2018

DURECT Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies to treat chronic debilitating diseases and enable biotechnology products. These platform technologies include the SABER® Delivery System (a patented and versatile depot injectable useful for proteins, peptides and small molecule delivery), the ORADUR® sustained release oral gel-cap technology (an oral sustained release technology with several potential abuse deterrent properties), the TRANSDUR® transdermal patch technology, the DURIN® Biodegradable Implant (drug-loaded implant system) and the MICRODUR™ Biodegradable Microparticulates (microspheres injectable system). DURECT also partners with pharmaceutical and biotechnology companies to develop and commercialize proprietary and enhanced pharmaceutical products based on its technologies. DURECT has seven disclosed on-going development programs of which six are in collaboration with pharmaceutical partners. DURECT’s strategy is to capitalize on the wealth of opportunities afforded by our proprietary platform technologies in three ways: To internally develop promising products based on our technologies To partner some of our product opportunities with development and/or commercialization partners at appropriate stages along the development timelines; and To make our technologies, along with our pre-clinical and clinical development expertise available to partners with the desire to develop proprietary extended or controlled release formulations of a wide range of molecules. The statements within the DURECT Corporation website, and affiliated websites, relating to DURECT's products in development, technology attributes or capabilities, product development plans, development timelines, expected product or technology benefits or potential product markets involve risks and uncertainties that could cause actual results to differ materially from those in such forward looking statements. Potential risks and uncertainties include, but are not limited to, our ability to develop and commercialize our products, our ability to complete successful clinical trials, our ability to obtain product approvals from regulatory agencies, marketplace acceptance of our products, our ability to successfully manufacture our products, our reliance on sole or limited suppliers, our ability to obtain adequate reimbursement from third-party payors and the introduction of competitive products by other companies, our ability to gain access to proprietary technology and drugs, our ability to enter into development or commercialization agreements with other life sciences companies, our ability to manage our growth and costs and relationships with third parties and finance our activities and operations. Further information regarding these and other risks is included in the company's S-1 registration statement, quarterly reports on Form 10-Q and annual report on Form 10-K, as filed with the SEC. Copies of these documents are available on request from the Investor Relations Department of DURECT

Chief Financial Officer
2000 - 2006

Vermillion, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. The company's bio-analytical solutions helps physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion was founded on December 9, 1993 and is headquartered in Austin, TX.

Chief Financial Officer
1999 - 2000

Avocet Medical, Inc. is an American private company located in San Jose, CA. The firm provides a hand held point of care testing device used to monitor patients undergoing anticoagulation therapy.

Boards & Committees
Board Member
Prior
Transactions
Details Hidden

DURECT Corp. issued Common Stock

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Matthew J. Hogan. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Matthew J. Hogan's profile does not indicate a business or promotional relationship of any kind between RelSci and Matthew J. Hogan.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/matthew-j-hogan-3238247
  • https://relationshipscience.com/person/matthew-j-hogan-3238247